Clinical Trial Update: Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) [Phase 3]

View source ↗

Summary

Phase 3 study evaluating MBG453 in combination with azacitidine in adults with intermediate/high/very high risk myelodysplastic syndromes (per IPSS-R) or chroni…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes
• Myelomonocytic Leukemia

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• MBG453

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic | Phase 3 | Status: TERMINATED | Results posted: 2025-12-12